Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
04 2019
Historique:
received: 12 06 2018
accepted: 23 11 2018
revised: 23 10 2018
pubmed: 16 12 2018
medline: 30 4 2019
entrez: 16 12 2018
Statut: ppublish

Résumé

Metastasis to distant organs is a major cause for solid cancer mortality, and the acquisition of migratory and invasive phenotype is a key factor in initiation of malignancy. In this study we investigated the contribution of Mixed-Lineage Kinase 4 (MLK4) to aggressive phenotype of breast cancer cells. Our TCGA cancer genomic data analysis revealed that amplification or mRNA upregulation of MLK4 occurred in 23% of invasive breast carcinoma cases. To find the association between MLK4 expression and the specific subtype of breast cancer, we performed a transcriptomic analysis of multiple datasets, which showed that MLK4 is highly expressed in triple-negative breast cancer compared to other molecular subtypes. Depletion of MLK4 in cell lines with high MLK4 expression impaired proliferation and anchorage-dependent colony formation. Moreover, silencing of MLK4 expression significantly reduced the migratory potential and invasiveness of breast cancer cells as well as the number of spheroids formed in 3D cultures. These in vitro findings translate into slower rate of tumor growth in mice upon MLK4 knock-down. Furthermore, we established that MLK4 activates NF-κB signaling and promotes a mesenchymal phenotype in breast cancer cells. Immunohistochemical staining of samples obtained from breast cancer patients revealed a strong positive correlation between high expression of MLK4 and metastatic potential of tumors, which was predominantly observed in TNBC subgroup. Taken together, our results show that high expression of MLK4 promotes migratory and invasive phenotype of breast cancer and may represent a novel target for anticancer treatment.

Identifiants

pubmed: 30552384
doi: 10.1038/s41388-018-0618-0
pii: 10.1038/s41388-018-0618-0
pmc: PMC6484767
doi:

Substances chimiques

NF-kappa B 0
MAP Kinase Kinase Kinases EC 2.7.11.25
MAP3K21 protein, human EC 2.7.11.25

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2860-2875

Références

Nat Rev Mol Cell Biol. 2002 Sep;3(9):663-72
pubmed: 12209126
Science. 2003 May 9;300(5621):949
pubmed: 12738854
J Clin Invest. 2004 Aug;114(4):569-81
pubmed: 15314694
J Clin Oncol. 2006 Dec 20;24(36):5652-7
pubmed: 17116942
Nat Methods. 2007 Apr;4(4):359-65
pubmed: 17396127
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Cancer Res. 2008 Mar 1;68(5):1462-70
pubmed: 18316610
Cancer Cell. 2009 May 5;15(5):416-28
pubmed: 19411070
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Eur J Cancer. 2010 May;46(7):1177-80
pubmed: 20307970
Breast Cancer Res Treat. 2011 Apr;126(2):407-20
pubmed: 20490655
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Mol Immunol. 2012 Jan;9(1):27-33
pubmed: 21602844
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Oncogene. 2012 Mar 1;31(9):1196-206
pubmed: 21785460
Cancer Res. 2012 Mar 1;72(5):1290-300
pubmed: 22253230
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Drug Discov Today. 2013 Mar;18(5-6):240-9
pubmed: 23073387
Cancer Res. 2013 Mar 15;73(6):1912-21
pubmed: 23319808
Oncogenesis. 2012 Mar 26;1:e6
pubmed: 23552557
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
J Vis Exp. 2014 Apr 25;(86):null
pubmed: 24797513
Nat Commun. 2014 May 22;5:3901
pubmed: 24849047
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
PLoS One. 2015 Apr 07;10(4):e0122333
pubmed: 25848952
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Arch Gynecol Obstet. 2016 Feb;293(2):247-69
pubmed: 26341644
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Trends Pharmacol Sci. 2015 Dec;36(12):822-846
pubmed: 26538316
Cancer Res. 2016 Feb 1;76(3):724-35
pubmed: 26637668
Cancer Cell. 2016 Feb 8;29(2):201-13
pubmed: 26859459
J Cell Physiol. 2017 Jun;232(6):1337-1345
pubmed: 27662245
PLoS One. 2017 Jan 20;12(1):e0169622
pubmed: 28107418
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
Cell Signal. 2017 Nov;39:66-73
pubmed: 28757353
J Biol Chem. 1997 Aug 22;272(34):21096-103
pubmed: 9261113

Auteurs

Anna A Marusiak (AA)

Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland. a.marusiak@cent.uw.edu.pl.

Monika K Prelowska (MK)

Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.

Dawid Mehlich (D)

Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Genomic Medicine, Medical University of Warsaw, Warsaw, Poland.

Michal Lazniewski (M)

Laboratory of Functional and Structural Genomics, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Department of Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.

Klaudia Kaminska (K)

Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.

Adam Gorczynski (A)

Department of Pathomorphology, Medical University of Gdansk, Gdańsk, Poland.

Aleksandra Korwat (A)

Department of Pathomorphology, Medical University of Gdansk, Gdańsk, Poland.

Olga Sokolowska (O)

Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.
Department of Immunology, Medical University o``f Warsaw, Warsaw, Poland.

Hanna Kedzierska (H)

Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.

Jakub Golab (J)

Department of Immunology, Medical University o``f Warsaw, Warsaw, Poland.
Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.

Wojciech Biernat (W)

Department of Pathomorphology, Medical University of Gdansk, Gdańsk, Poland.

Dariusz Plewczynski (D)

Laboratory of Functional and Structural Genomics, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Faculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland.

John Brognard (J)

National Cancer Institute, Frederick, MD, USA.

Dominika Nowis (D)

Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Genomic Medicine, Medical University of Warsaw, Warsaw, Poland.
Department of Immunology, Medical University o``f Warsaw, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH